- Capital Cube•15 days ago
Categories: Yahoo Finance Click here to see latest analysis Merck KGaA reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Merck KGaA – Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Amgen Inc., Abbott Laboratories, Biogen Inc. and ARIAD Pharmaceuticals, Inc. (BMY-US, PFE-US, MRK-US, AMGN-US, ABT-US, ... Read more (Read more...)
- PR Newswire•2 months agoJuniper Pharmaceuticals Announces that Merck KGaA, Darmstadt, Germany, has Obtained Regulatory Approval for OneCrinone® in Japan
BOSTON, July 5, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that for the Japanese market Merck KGaA, Darmstadt, Germany (XETRA:MRK.DE), acting through its biopharma business, has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for OneCrinone® 90 mg (progesterone) for the indication of luteal phase supplementation in assisted reproductive treatment. "This approval further expands the global Crinone® progesterone gel franchise into the world's' third largest pharmaceutical market, giving women and couples struggling with infertility in Japan a new, patient-friendly therapeutic option for luteal phase support," said Frank Condella, Juniper's CEO. Merck KGaA, Darmstadt, Germany, has worldwide marketing rights to Crinone® except in the United States, where Crinone® is marketed by Allergan, Inc. (AGN). Outside the U.S., Merck KGaA, Darmstadt, Germany, holds the marketing authorization for Crinone® in over 90 countries.
- PR Newswire•2 months agoMerck KGaA, Darmstadt, Germany, Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced together with Illumina Inc., San Diego, US, and Genea Limited, Sydney, Australia, that the Global Fertility Alliance welcomed two new members. The alliance is a collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory.
Merck KGaA (MKGAY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||36.24 - 36.42|
|52wk Range||35.84 - 37.16|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||30.56|
|Avg Vol (3m)||3,443|
|Dividend & Yield||0.40 (1.10%)|